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Background: Ideal postoperative pain management requires a multidisciplinary approach
in combination with a variety of dosage regimens. Approximately 21–30% of patients
experience moderate to severe pain in the postoperative period, which may have a sig-
niﬁcant impact on recovery rate, standard of living, psychological health, and postoperative
complications.
Objective: Analysis of the incidence and characterization of reported adverse effects with
DepoFoam bupivacaine compared to conventional bupivacaine or placebo.
Methods: A systematic review of prospective studies on the use of DepoFoam versus
bupivacaine or placebo was performed in order to answer the clinically relevant question:
is DepoFoam a safer formulation in place of bupivacaine single injection or continuous
local infusion techniques for postoperative pain management? Inclusion criteria required
randomized, controlled, double-blind trials in patients 18 years old or older, single dose
used for postoperative pain control, and a primary procedure performed.
Results: Six studies ﬁtted the inclusion criteria for analysis, DepoFoam bupivacaine used in
therapeutic doses was well-tolerated, had a higher safety margin, and showed a favorable
safety proﬁle compared to bupivacaine and control groups.
Conclusion: Extended drug delivery system DepoFoam bupivacaine is a promising drug
formulation that may signiﬁcantly improve postoperative care and pain control in surgical
patients.
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INTRODUCTION
An estimated 70 million surgical procedures are being performed
annually in the United States (Cullen et al., 2009; Hall et al., 2010).
Approximately 21–30% of these patients experience moderate to
severe pain in the postoperative period, which may have a signif-
icant impact on their recovery, standard of living, psychological
health, and the rate of postoperative complications. Additionally,
healthcare costs of chronic pain developing from acute pain may
constitute an enormous ﬁnancial burden for both the patient and
the community. The lifetime economic costs of a single 30-year-
old patient suffering from chronic pain will reach onemillion U.S.
dollars (Apfelbaum et al., 2003).
An ideal postoperative pain management requires a multi-
modal and multi-disciplinary approach with a combination of
various therapeuticmaneuvers, acting atmultiple levels of the ner-
vous system and interfering with different pain propagation and
perception mechanisms. Such a strategy will improve the over-
all results, ensure a higher level of postoperative analgesia, and
reduce the possibility of side-effects including nausea, vomiting,
constipation, and respiratory depression (Kehlet and Dahl, 2003).
Additionally, an effective pain management control will shorten
the inpatient time, reduce the rates of postsurgical complications
and readmissions, prevent opioid dependence and, potentially,
reduce mortality (White and Kehlet, 2010).
Currently adopted treatment protocols include various com-
binations of systemically or epidurally administered opioids,
non-steroidal anti-inﬂammatory drugs, peripheral and neuraxial
blocks andwhen indicated, supplementationwith antidepressants,
N-methyl D-aspartate (NMDA) antagonists and other centrally
acting medications (Kehlet and Dahl, 2003; Bergese et al., 2011;
Nigam et al., 2011).
Regional and local anesthesia plays an important role in post-
operative pain control. In addition to effective analgesia, local
anesthetics block the afferent neural stimuli from the surgical area,
reducing endocrine-metabolic responses without any effects on
inﬂammation (Kehlet and Dahl, 2003). Long-acting amide local
anesthetics such as ropivacaine and bupivacaine provide a superior
pain control over opioids and are commonly used in the postoper-
ative period for inﬁltrative, regional, and neuraxial blocks (Ersayli
et al., 2006; Kuthiala and Chaudhary, 2011; Sakai et al., 2013).
Local anesthetics exert their effects via blocking the voltage-gated
sodium channels on the cell membrane, thereby interfering with
afferent signal propagation, thus reducing hyperalgesia and allo-
dynia (Lai et al., 2004). Mechanically, some of these actions are
achieved by a variable degree of blocking the potassium (K+),
calcium (Ca2+) channels, and NMDA receptors.
Bupivacaine hydrochloride (HCl) is a widely used local anes-
thetic with prolonged duration of action. The drug is administered
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for local postoperative pain control either as a single bolus injec-
tion or continued infusion. In a study done by Borgeat et al.
(2003) the average duration of interscalene block after a bolus
injection varied between 8 to 12 h with either bupivacaine 0.5%
or ropivacaine 0.5 or 0.75%. Apparently, the single bolus injec-
tion technique is not a sufﬁcient method for postoperative pain
management in most cases. On the other hand, placement and
maintenance of perineural catheters for extended pain control
will require additional training and skills for the clinicians, will be
more costly, and will have a higher rate of complications (Chahar
and Cummings, 2012). Thus, the development of novel, longer-
acting local anesthetic formulations, like liposomal bupivacaine,
is important to improve the management of postoperative pain
(Chahar and Cummings, 2012).
A newer, extended-release formulation of bupivacaine, Depo-
Foam bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc., Par-
sippany, NJ, USA), was approved in the U.S. by the Federal
Drug Administration (FDA) in October 2011. This innovative
delivery system consists of biocompatible, biodegradable, spher-
ical, lipid-based particles ranging in size between 10–30 μm
and containing encapsulated drug designed to allow diffusion
over an extended duration of time (Bergese et al., 2011; Cha-
har and Cummings, 2012). The encapsulated bupivacaine has
a slower elimination half-life due to its slow release from the
vehicle and decreased absorption rate from the injection site,
resulting in sustained local analgesia (Bergese et al., 2011; Chahar
and Cummings, 2012). The bupivacaine DepoFoam formu-
lation has a bimodal plasma concentration time proﬁle with
an initial peak at 0.25–2 h and a second peak at 12–24 h
after injection (Bergese et al., 2011). The liposomal formula-
tion of bupivacaine is intended for a single-dose inﬁltration into
the surgical site for prolonged postsurgical analgesia lasting up
to 72 h (About DepoFoam, 2011). DepoFoam bupivacaine is
mainly metabolized via hepatic conjugation and N-dealkylation
of bupivacaine (Chahar and Cummings, 2012). Although, the
bupivacaine and pipecolylxylidine (metabolite) concentrations
are higher in patients with moderate hepatic impairment com-
pared to patients with normal hepatic function, the differences
are not clinically signiﬁcant and do not require any dose adjust-
ments according to the FDA guidelines (Chahar and Cummings,
2012).
SAFETY PROFILE
The most signiﬁcant adverse effects (AEs) of bupivacaine are
primarily related to its cardiovascular and neurotoxic properties
(Pacella et al., 2010). The drug is 6 to 10 times more cardiotoxic
than lidocaine, an effect attributed to the blockade of sodium,
potassium, and L-type calcium channels in the sarcolemma of
cardiomyocytes that produce a conduction block, reduce contrac-
tility, depress automaticity (spontaneous phase IVdepolarization),
and reduce the duration of the refractory period (Kiuchi et al.,
2011; Chahar andCummings,2012). Bupivacaine-induced cardiac
arrests are more resistant to resuscitative interventions compared
to other local anesthetics (Beilin and Halpern, 2010). Bupivacaine
can also induce Ca2+-induced apoptosis of muscle cells, a com-
plication described after performing retrobulbar and peribulbar
blocks (Chahar and Cummings, 2012).
An important question arises as to whether or not this lipo-
somal delivery system will lead to fewer AEs and have a better
safety proﬁle when compared to a placebo group or a conventional
bupivacaine formulation. Despite experimental evidence (Richard
et al., 2011), there have been no reports in the current literature of
post-injection granuloma formation in humans.
A comprehensive review on the pharmacological characteris-
tics of the sustained-release liposome formulation DepoFoam has
become recently available (Chahar and Cummings, 2012). Nev-
ertheless, from a clinician’s point of view, it would be extremely
valuable to summarize the existing limited literature reports on
DepoFoam bupivacaine’s efﬁcacy, tolerability, and safety proﬁle.
METHODS
We reviewed published prospective studies within the last 5 years
on head to head comparison of DepoFoam versus bupivacaine
or placebo to answer the clinically relevant question whether
DepoFoam would be a safer formulation capable of replac-
ing bupivacaine single injection or continuous local infusion
techniques in the postoperative pain management.
We also conducted a systematic review of published, ran-
domized controlled trials that detailed the AEs of DepoFoam in
comparison to a placebo group or a conventional bupivacaine
formulation.
Two individual investigators conducted separate litera-
ture searches to isolate clinical trials that reported on
the AEs of DepoFoam bupivacaine in the postoperative
period. Using the preferred reporting items for systematic
reviews and meta-analysis (PRISMA) guidelines, a search
in PubMed, Scopus, and the Cochrane Library was per-
formed in March of 2013 with the following keywords: Depo-
Foam, bupivacaine, liposome bupivacaine, bupivacaine HCl, and
Exparel.
The following inclusion criteria were used:
(1) Randomized controlled double blind trials in patients aged 18
or older.
(2) Use of a single dose of DepoFoam bupivacaine for postopera-
tive pain control.
(3) A primary procedure was performed (i.e., not a salvage or
follow-up procedure).
The objective of this analysis was to identify the most com-
mon reportedAEs experiencedwith escalating doses of DepoFoam
bupivacaine when compared to conventional bupivacaine or
placebo. A sub-analysis of the most common AEs related to
treatment was also conducted and interpreted.
RESULTS
A total of 16 articles pertaining to DepoFoam bupivacaine were
identiﬁed through the initial search. However, only six stud-
ies ﬁtted the inclusion criteria for analysis. These studies were
conducted based on proper obtainment of written informed
consent, strict adherence to the amendments of the Declara-
tion of Helsinki, the Good Clinical Practices guidelines, and
approval of the Institutional Review Board (IRB). The types of
surgeries encompassed were total knee arthroplasty (Bramlett
et al., 2012), bunionectomy (Golf et al., 2011), hemorrhoidectomy
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(Gorﬁne et al., 2011), breast augmentation (Smoot et al., 2012;
Minkowitz et al., 2012), and a study conducted on healthy volun-
teers (Naseem et al., 2012). The AEs were reported as deemed
appropriate by the investigator and the relationship to study
drug administration was categorized as clinical or non-clinical
signiﬁcant.
The randomization groups and demographic data for the six
studies are outlined in Table 1.
Bramlett et al. (2012) conducted a randomized, double-blind,
dose-ranging study of DepoFoam bupivacaine compared to bupi-
vacaine HCl in a phase 2 trial of 138 patients undergoing total
knee arthroplasty. All the doses of DepoFoam bupivacaine and
bupivacaine HCl were reported to be well tolerated and safe. No
signiﬁcantAEswere attributed to the study drug, and the incidence
rate of AEs for bupivacaineDepoFoamwere similar to those found
for bupivacaine HCl.
Golf et al. (2011) conducted a phase 3, randomized,
placebo-controlled, double-blind studyof DepoFoambupivacaine
in 193 bunionectomy patients. The study authors concluded that
DepoFoam bupivacaine 120 mg was well tolerated and safe and it
provided a higher level of analgesia. Analgesia level was assessed
using the area under the curve (AUC) for the pain numeric rat-
ing scale during 24 h, the pain-free period, and the use of opioids.
The incidence of medication-relatedAEs and severe adverse events
(SAE) were higher for the DepoFoam bupivacaine group (9.3
versus 5.2 % and 11.3 versus 5.2%, respectively). However, the
incidence of moderate AEs was found to be higher for the placebo
group. In fact, the only AE that had a signiﬁcantly higher occur-
rence rate in the DepoFoam group was postoperative nausea and
vomiting (PONV), a well-known side effect of bupivacaine injec-
tion. Because the study was designed to compare DepoFoam with
placebo, no conclusions could be made regarding the incidence of
Table 1 | Randomization groups and demographic characteristics.
Study Dose n Mean age and
standard
deviation (SD)
Males Females Surgery
Bramlett et al. (2012)
n = 138
*134 patients completed the study.
DepoFoam 133 mg
DepoFoam 266 mg
DepoFoam 399 mg
DepoFoam 532 mg
Bupivacaine HCl 150 mg
27
25
26
24
32
61.4 (7.0)
61.1 (8.7)
61.8 (6.3)
64.9 (7.3)
62.2 (7.2)
53 85 Knee arthroplasty
Golf et al. (2011)
n = 193
*185 patients completed the study.
DepoFoam 120 mg
Placebo
93
92
42.4 (12.7)
43.3 (13.4)
34 159 Bunionectomy
Gorﬁne et al. (2011)
n = 189
*186 patients completed the study.
DepoFoam 300 mg
Placebo
95
94
48.0 (12.2)
48.7 (11.9)
130 59 Hemmorrhoidectomy
Minkowitz et al. (2012)
n = 94
*94 patients completed the study.
DepoFoam 150 mg +
bupivacaine HCl 75 mg
DepoFoam 266 mg +
bupivacaine HCl 75 mg
17
14
32.2 (7.2)
29.3 (6.3)
N/A 17
14
Augmentation mammoplasty
DepoFoam 532 mg 31 32.9 (7.6) 31
Bupivacaine HCl 200 mg 32 30.8 (7.1) 32
Naseem et al. (2012)
n = 49
*46 patients completed part 1 of the study.
*16 patients completed part 2 of the study.
Varying doses 49 26 (5) 34 15 Healthy volunteers
Smoot et al. (2012)
n = 136
*82 patients completed the study.
DepoFoam 600 mg
Bupivacaine HCl 200 mg
64
70
30.8 (7.3)
30.6 (7.6)
N/A 134 Augmentation mammoplasty
Total: n = 743
*The actual number of patients who completed the study which was different from the n number.
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PONV in the DepoFoam bupivacaine group versus conventional
bupivacaine group. Above all, the AEs were considered to be unre-
lated to therapy, and no statistically signiﬁcant changes were found
in blood tests, except for two cases of elevated creatinine levels in
the DepoFoam group.
Gorﬁne et al. (2011) conducted a phase 3 randomized, double-
blind, placebo-controlled trial of 300 mg DepoFoam bupivacaine
in 189 patients undergoing hemorrhoidectomy. The cumulative
pain score was assessed during the ﬁrst 72 h after study drug
administration using the AUC of pain intensity. The incidence
and amount of opioid rescue medication used, time to initial use
of a rescue drug, and the level of patient satisfaction were also
measured (Gorﬁne et al., 2011). Use of DepoFoam bupivacaine
resulted in a statistically signiﬁcant improvement in all the above
mentioned parameters when compared with placebo.
This study found that administration of DepoFoam bupiva-
caine at a dose of 300mg was safe and well tolerated in all patients.
The only AE attributed to the study drug was a single case of
ﬁngernail redness that resolved on day 6 without any intervention.
Minkowitz et al. (2012) reported on the clinical sequelae
noted on 94 female patients who had undergone augmenta-
tion mammoplasty, during a 2-year follow-up period. The paper
included two studies: a phase II, active-controlled, randomized,
double-blind, multi-center study, and a phase III, randomized,
double-blind, multi-center study. Both studies reported that the
DepoFoam bupivacaine was well tolerated and no SAEs were
reported. Moreover, the AEs of mild or moderate intensity were
not deemed to be related to the study medication. Overall, the
study found no signiﬁcant tolerability difference between the two
arms of either study. The authors concluded that administra-
tion of the DepoFoam bupivacaine would not have a negative
effect on the integrity of breast implants at 2 years after the
surgery.
Naseem et al. (2012) characterized the effects of subcutaneous
administration of DepoFoam bupivacaine of varying doses on
the QTc interval in 49 healthy volunteers. The study consisted of
two parts: part 1 was a single-center, randomized, placebo- and
positive-controlled, double-blind, double-dummy, and crossover
study that involved a sequence of four treatments (400 mg mox-
iﬂoxacin, 300 mg DepoFoam bupivacaine, 450 mg DepoFoam
bupivacaine, and a placebo group), whereas part 2 was a single-
center, sequential-dose, exploratory extension to test a higher dose
of DepoFoam that involved a sequence of three treatments (600mg
DepoFoam bupivacaine, 750 mg DepoFoam bupivacaine, and a
placebo).
In the ﬁrst part of the study, all doses of DepoFoam were
reported to be well tolerated by the healthy participants. One
SAE (acute hepatitis A with eosinophilia) was reported in the
450 mg DepoFoam formulation group that was deemed unrelated
to DepoFoam treatment. Sixty (60) AEs were reported by 25
FIGURE 1 | Most common adverse effects reported (incidence above 5.0%).
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participants in the part 1 study, of which 17 were considered
treatment-related (pooled data from DepoFoam bupivacaine and
moxiﬂoxacin treatment groups). The most common AEs experi-
enced in the DepoFoam bupivacaine group included abdominal
pain, injection site irritation, headaches, nervousness, gastroin-
testinal, and respiratory/thoracic symptoms. In part 2, no SAEs
were reported. A total of 43 AEs were reported by ten patients,
of whom eight were deemed to be treatment-related (pooled data
from DepoFoam and moxiﬂoxacin treatment groups). The most
common AEs reported by participants in the second part of the
study were injection site erythema, pruritus, injury, poisoning,
nervous system, and gastrointestinal disorders, with no additional
information provided by the authors. In relation to our objec-
tive, all four doses of DepoFoam bupivacaine across both studies
failed to show any clinically signiﬁcant effects on the QTc inter-
val, leading the researchers to conclude that doses up to 750 mg
ofDepoFoam bupivacaine pose no cardiac concern, with no QT
interval prolongation.
Smoot et al. (2012) conducted a randomized, active-controlled,
multi-center, double-blind study of 136 female patients undergo-
ing bilateral augmentation mammoplasty. This was a double-arm
study comparing DepoFoam bupivacaine 600 mg to conventional
bupivacaine HCl 200 mg. There were no SAEs reported for either
arm. A total of 99 patients (72.8%), with 48 patients in DepoFoam
bupivacaine group and 51 patients in the bupivacaine HCl group,
reported at least one AE. The majority of AEs were mild or mod-
erate in severity. Given the comparable safety proﬁles of the two
administrations, and the lack of treatment-related seriousAEs, the
study concluded that DepoFoam bupivacaine was well tolerated
in patients undergoing augmentation mammoplasty, even though
the study was underpowered to achieve statistical signiﬁcance.
A summary of the most common AEs reported (above 5.0%
incidence) in the trials are outlined in Figure 1.
DISCUSSION
The balance between drug efﬁcacy and safety remains at the
forefront of debate regarding postsurgical pain management.
Current clinical practices include the use of opioid and non-
opioid analgesics along with various regional anesthesia tech-
niques combined with alternative methods and medications,
when indicated. Local anesthetics and bupivacaine in partic-
ular, are known to cause serious cardio- and neurotoxic side
effects (Srinvivasa et al., 2003; Yang et al., 2011; Bergese et al.,
2012; Oda and Ikeda, 2013). The introduction of the liposome
extended-release bupivacaine formulation used for the postop-
erative pain control provides a new and promising method,
leading to signiﬁcant changes in patient management. Current
experimental data suggest that lipid emulsion-based bupivacaine
solutions have a higher safety margin compared to conventional
bupivacaine. Oda and Ikeda (2013) showed through an in vivo
model that higher doses (above 300 mg) of lipid bupivacaine
are required to induce convulsions (neurotoxicity) and cardiac
arrest.
This review summarizes the results reported in six studies
on the safety proﬁle of DepoFoam bupivacaine used in inﬁltra-
tive anesthesia for postoperative pain control. In these reports,
the authors compared DepoFoam bupivacaine with conventional
bupivacaine solution, and control medication or placebo. In gen-
eral, the ﬁndings indicated that DepoFoam bupivacaine used in
therapeutic doseswaswell-tolerated, and showed a favorable safety
proﬁle compared to bupivacaine and controls. Golf et al. (2011)
reported two cases of blood creatinine elevation in the DepoFoam
group. Unfortunately, the authors did not describe whether these
changes were related to drug use or othermedical conditions (Golf
et al., 2011). Additionally, Gorﬁne et al. (2011) reported a patient
in the DepoFoam bupivacaine group, who experienced ﬁnger nail
redness on day 2, which was considered by the investigator to be
related to the study drug.
For future studies, a better-powered double-blind prospec-
tive trial with a higher number of patients will be required to
address the questions regarding the actual incidence rate of AEs
and their severity. Additionally, future studies should focus on
drug use during different surgical procedures, targeting patients
with various comorbidities, particularly kidney dysfunction and
dyslipidemia. It would be clinically relevant to assess the inci-
dence of PONV in randomized patient groups undergoing various
surgical interventions and receiving bupivacaine or DepoFoam
bupivacaine for postoperative pain control. It will also be impor-
tant to take into account the relatively large size of the lipid
multivesicular liposomes (10–30 μm) which lengthens the time
of local anesthetic action by slowing release from the liposome,
furthermore, delaying the peak plasma concentration (Chahar
and Cummings, 2012). Additionally, the effects of DepoFoam
bupivacaine on the blood lipid proﬁle and the development of
hemorrhagic anemia with the administration of high-dose Depo-
Foam is a side effect worth further evaluation, whether this may
be a drug-induced vasculitis, thrombophlebitis, or a possible lipid
microembolism.
In conclusion, extended drug delivery system of DepoFoam
bupivacaine is a promising drug formulation which may signiﬁ-
cantly improve the postoperative pain control in surgical patients.
Further studies with larger patient groups are needed to enhance
the current level of knowledge of the drug’s advantages and
disadvantages, and deﬁne the areas of best application.
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